Tremfya (guselkumab) - J&J
Omvoh (mirikizumab-mrkz) - Eli Lilly
tofacitinib - Generic mfg.
Stelara (ustekinumab) - J&J
Jyseleca (filgotinib) - Gilead
Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim
Rinvoq (upadacitinib) - AbbVie
Zeposia (ozanimod) - BMS
Velsipity (etrasimod) - Pfizer
http://www.ncbi.nlm.nih.gov/pubmed/42117726
 
; Alex Hwong-Ruey Leow; Byong Duk Ye; Choon Jin Ooi; Govind Makharia; Hang Dao Viet; Huiyu Lin; Ida Hilmi; Jose Sollano; Joyce Wing Yan Mak; Julajak Limsrivilai; Kai Chun Wu; Katsuyoshi Matsuoka; Khoon Lin Ling; Luan Minh Dang; Malcolm Tan; Marcellus Simadibrata; Mathew Philip; Meng-Tzu Weng; Nazri Mustaffa; Nik Razima Wan Ibrahim; Pises Pisespongsa; Raja Affendi Raja Ali; Rupert W Leong; Ryota Hokari; Satimai Aniwan; Shu-Chen Wei; Siew-Chien Ng; Taku Kobayashi; Vineet Ahuja; Wai-Keung Leung; Wan Chee Ong; Wee-Chian Lim; Wei Jie Jonathan Lee; Zhi Hua Ran
 
May 12, 2026
 
Prev Next